Foghorn Therapeutics FHTX Cash Flow Statement (2019-2026)

NASDAQ FHTX
$2.09 +0.19 (+10.00%)
At close: Nov 11, 2026 · 4:00 PM EST
Reported Financials

Foghorn Therapeutics Quarterly Cash Flow Statement

Periods 29 quarters
Latest Sep 2026

Foghorn Therapeutics reported cash from operations of -$18.24M and free cash flow of -$18.25M for the quarter ended Sep 2026, up 3.3% year over year. This cash flow statement covers 29 quarters of results from Sep 2019 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
-29.12M-26.91M-27.31M-25.77M-28.90M-30.49M-29.49M-14.35M-24.11M-25.02M-22.98M-19.12M-19.50M-18.83M-17.94M-15.85M-21.68M-19.88M-7.19M58.15M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
0.81M0.81M0.80M0.90M0.82M0.90M0.80M0.90M0.90M0.84M0.80M0.70M0.72M0.83M0.90M0.90M0.80M0.24M0.20M0.20M
Share-based CompensationStock Comp.
2.08M3.24M3.51M3.80M3.78M4.57M4.47M4.09M3.05M3.22M3.17M3.02M2.48M2.69M2.73M2.73M2.24M2.38M2.55M2.52M
Gains from Sales and DivestituresGains Divest
-0.01M
Asset Writedowns and ImpairmentWritedown
2.40M0.00M5.91M
Other non-cash itemsOther Non-Cash
1.29M-0.77M-0.73M-0.66M-0.50M-0.55M3.42M1.39M1.43M1.45M1.52M0.70M-1.09M0.56M0.54M0.52M
Change in Working Capital
Change in ReceivablesChange Receivables
-300.00M300.00M
Change in Account PayablesChange Payables
-0.02M1.27M-1.44M1.62M0.16M1.69M-0.17M-0.44M-0.24M-0.63M-0.83M-1.35M0.33M0.28M-0.75M-0.11M1.05M-0.99M-0.07M-1.03M
Change in Accrued ExpensesChange Accrued Exp.
2.40M-2.54M1.09M2.00M0.89M-2.15M-0.67M0.69M0.33M-2.81M-0.30M4.97M-2.42M-2.41M2.02M1.16M1.44M-4.46M1.06M4.52M
Change in Other Operating AssetsOther Assets Change
303.22M-299.07M1.36M-0.85M3.45M0.31M1.55M0.65M1.95M0.09M-1.88M-0.76M1.24M-1.07M-0.92M-1.34M0.50M0.09M-0.72M-0.35M
Change in Other Operating LiabilitiesOther Liabilities Change
335.40M-5.67M-6.26M-3.43M-5.85M-6.98M-7.50M-19.42M-7.78M-7.14M-8.99M-9.61M-4.80M-8.23M-9.91M-9.32M-10.19M-2.65M-15.07M-82.88M
Other Working Capital ChangesOther WC Changes
32.18M293.40M-7.62M-2.58M-9.29M-7.29M-9.05M-20.07M-9.73M-7.24M-7.11M-8.85M-6.03M-7.16M-8.99M-7.98M-10.69M-2.74M-14.35M-82.53M
Cash from OperationsCash from Ops.
11.88M271.53M-29.01M-19.99M-28.92M-31.18M-32.18M-27.21M-27.54M-29.35M-25.54M-21.01M-24.52M-23.97M-21.00M-18.86M-22.27M-25.27M-17.84M-18.24M
Investing Activities
Capital ExpendituresCapex
0.08M0.25M0.36M0.33M0.27M0.64M0.47M0.08M0.04M0.10M0.02M0.31M0.48M0.03M0.02M0.05M0.01M
Change in Property, Plant and EquipmentChange in PP&E
-0.08M-0.25M-0.36M-0.33M-0.27M-0.64M-0.47M-0.08M-0.04M-0.10M-0.02M-0.31M-0.48M-0.03M-0.02M-0.05M-0.01M
Purchase of InvestmentsInvestments Purchased
10.25M212.29M143.09M9.62M44.34M26.23M36.97M3.86M6.84M31.26M66.10M124.45M39.65M51.12M42.14M4.00M33.98M66.94M37.08M13.60M
Sale and Maturity of InvestmentsInvestments Sold
20.00M53.13M19.00M56.00M38.10M56.37M76.57M42.37M44.26M58.46M48.15M63.45M62.42M80.55M76.00M39.58M47.21M49.22M34.17M37.80M
Other Investing Activities (as filed)Other investing (as filed)
1.73M1.73M1.71M1.71M1.54M3.25M-1.25M
Cash from Investing ActivitiesCash from Investing
9.67M-159.41M-124.46M46.05M-6.51M29.51M39.13M38.43M37.39M27.10M-17.98M-61.32M22.29M29.40M33.83M35.57M13.23M-17.72M-2.97M24.19M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
Long-Term Debt RepaymentsLT Debt Repayment
21.21M
Net Long-Term Debt Issued (Repaid)Net LT Debt
-21.21M
Net Debt Issuances and RepaymentsNet Debt Issuance
-21.21M
Change in Capital Stock
Common Stock IssuedStock Issued
42.95M0.38M1.03M0.33M0.02M0.10M0.10M1.39M0.19M1.17M103.40M1.44M-103.40M0.14M0.25M0.05M0.04M50.09M0.01M-49.52M
Net Shares Issued and RepurchasedNet Shares Issued
42.95M0.38M1.03M0.33M0.02M0.10M0.10M1.39M0.19M1.17M103.40M1.44M-103.40M0.14M0.25M0.05M0.04M50.09M0.01M-49.52M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
42.95M0.38M1.03M0.33M0.02M0.10M0.10M1.39M0.19M1.17M103.40M1.44M-103.40M0.14M0.25M0.05M0.04M50.09M0.01M-49.52M
Other financing activities (as filed)
-0.39M-0.32M-0.03M
Cash from Financing ActivitiesCash from Financing
21.74M0.38M1.03M0.33M0.02M0.10M0.10M1.39M0.19M1.17M103.21M1.05M0.00M0.14M0.25M0.05M0.58M49.77M-0.02M6.28M
Additional items
Change in Cash
43.30M112.51M-152.44M26.40M-35.42M-1.57M7.06M12.60M10.03M-1.08M59.69M-81.27M-2.22M5.57M13.09M16.76M-8.46M6.79M-20.83M12.22M
Ending Cash Balance
102.87M215.38M62.94M89.34M53.92M52.35M59.41M72.01M82.04M80.96M140.66M59.39M57.16M62.73M75.82M92.58M84.13M90.91M70.08M82.30M
Free Cash FlowFCF
11.80M271.29M-29.38M-20.32M-29.19M-31.82M-32.64M-27.29M-27.58M-29.45M-25.55M-21.31M-25.00M-24.00M-21.02M-18.86M-22.27M-25.27M-17.89M-18.25M
Net Cash FlowNCF
43.30M112.51M-152.44M26.40M-35.42M-1.57M7.06M12.60M10.03M-1.08M59.69M-81.27M-2.22M5.57M13.09M16.76M-8.46M6.79M-20.83M12.22M
Interest Paid
0.50M
Income Taxes PaidTaxes Paid
1.69M1.00M0.87M0.05M0.71M0.06M0.05M0.00M0.00M0.00M0.00M

Foghorn Therapeutics Cash Flow Statement API

Pull Foghorn Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=FHTX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY